RxDoctor Payments Data

Mark Cohen, MD

Cardiovascular Disease · Albany, GANPI 1376545053

Payments from drug & device makers

$5,249in general payments, 2019–2025

Across 101 payments — averaging $51.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Penumbra, Inc.$1K
  • Vanda Pharmaceuticals Inc.$401
  • Abiomed$398
  • Shockwave Medical, Inc$344
  • E.r. Squibb & Sons, L.L.C.$270
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$3907%
  • Food & beverage$4,85993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,249 in reported general payments places this provider in the 65th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$74,736
Medicare patients
385
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$315,600
EntrestoSacubitril/Valsartan137$123,947
FarxigaDapagliflozin Propanediol126$111,786
XareltoRivaroxaban87$77,769
JardianceEmpagliflozin44$38,369
BrilintaTicagrelor26$14,486
Metoprolol Succinate647$7,096
Atorvastatin Calcium319$3,217
Spironolactone367$2,600
Ranolazine ErRanolazine30$2,572
ClopidogrelClopidogrel Bisulfate253$2,515
Rosuvastatin Calcium244$2,490
Valsartan111$2,101
Nitroglycerin183$1,685
Carvedilol250$1,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$315,600315 claims
AstraZenecaFarxiga, Brilinta$33$126,272152 claims
NovartisEntresto$215$123,947137 claims
Johnson & JohnsonXarelto$59$77,76987 claims
Boehringer IngelheimJardiance$16$38,36944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →